Kenvue Inc. (NYSE:KVUE – Get Free Report) announced a quarterly dividend on Thursday, October 17th, RTT News reports. Shareholders of record on Wednesday, November 13th will be paid a dividend of 0.205 per share on Wednesday, November 27th. This represents a $0.82 annualized dividend and a yield of 3.82%. The ex-dividend date of this dividend is Wednesday, November 13th.
Kenvue has a dividend payout ratio of 67.2% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Kenvue to earn $1.23 per share next year, which means the company should continue to be able to cover its $0.82 annual dividend with an expected future payout ratio of 66.7%.
Kenvue Price Performance
Shares of NYSE:KVUE opened at $21.46 on Friday. The company’s fifty day moving average price is $22.25 and its 200-day moving average price is $20.20. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68. The firm has a market capitalization of $41.08 billion, a price-to-earnings ratio of 27.51, a PEG ratio of 2.76 and a beta of 1.40. Kenvue has a one year low of $17.67 and a one year high of $23.55.
Analyst Ratings Changes
KVUE has been the subject of several analyst reports. UBS Group upped their price target on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Jefferies Financial Group started coverage on Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price target on the stock. Royal Bank of Canada downgraded Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price objective for the company. in a research report on Tuesday, September 24th. Citigroup cut their target price on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. Finally, Piper Sandler increased their price target on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and an average price target of $22.20.
Read Our Latest Stock Report on Kenvue
About Kenvue
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Read More
- Five stocks we like better than Kenvue
- 5 discounted opportunities for dividend growth investors
- UPS vs. FedEx: Which Stock Delivers Better Holiday Gains?
- What Are Dividend Achievers? An Introduction
- Insider Selling is not a Signal to Start Selling Gartner Stock
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Taiwan Semiconductor Soars on Earnings With More Room to Run
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.